---
title: "ALKS.US (ALKS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALKS.US/news.md"
symbol: "ALKS.US"
name: "ALKS.US"
parent: "https://longbridge.com/en/quote/ALKS.US.md"
datetime: "2026-05-20T06:46:07.268Z"
locales:
  - [en](https://longbridge.com/en/quote/ALKS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALKS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALKS.US/news.md)
---

# ALKS.US (ALKS.US) — Related News

### [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)
*2026-05-13T11:51:06.000Z*
> Alkermes has reported positive results from the Phase III REVITALYZ study of Lumryz (sodium oxybate) for treating idiopa

### [Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)](https://longbridge.com/en/news/286252932.md)
*2026-05-13T11:30:56.000Z*
> Wells Fargo analyst maintained a Buy rating on Alkermes today and set a price target of $44.00.Claim 55% Off TipRanksUnl

### [Sector Update: Healthcare Stocks Advance Late Afternoon](https://longbridge.com/en/news/286149036.md)
*2026-05-12T19:58:00.000Z*
> Healthcare stocks saw gains late Tuesday, with the NYSE Healthcare Index and the State Street Healthcare Select Sector S

### [Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles](https://longbridge.com/en/news/286142912.md)
*2026-05-12T18:27:41.000Z*
> Alkermes Inc. shares rose after positive phase 3 results for LUMRYZ in treating excessive daytime sleepiness linked to i

### [Sector Update: Healthcare Stocks Gain in Afternoon Trading](https://longbridge.com/en/news/286140558.md)
*2026-05-12T17:54:00.000Z*
> Healthcare stocks experienced gains on May 12, 2026, with the NYSE Healthcare Index up 2.1% and the State Street Healthc

### [Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH](https://longbridge.com/en/news/286137280.md)
*2026-05-12T17:25:19.000Z*
> Alkermes has achieved a significant milestone with its $2.37 billion acquisition of Avadel, as the phase 3 study of Lumr

### [Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment](https://longbridge.com/en/news/286107593.md)
*2026-05-12T13:00:00.000Z*
> Alkermes announced that its Phase 3 trial for Lumryz, an oral suspension for treating idiopathic hypersomnia, met all pr